The impact of increasing antimicrobial resistance in the treatment of urosepsis
- 35 Downloads
Background and aims
Urosepsis accounts for up to 20–30% of all sepsis cases; however, increasing antimicrobial resistance is posing a significant threat to patient’s outcomes. The aim of this study was to look at the prevalence of multi-drug resistant (MDR) organisms in patients admitted with urosepsis and their effect on the treatment and outcome of patients in our hospital.
A total of 2679 urine cultures and 654 blood cultures performed in Connolly Hospital Emergency Department were reviewed between 2016 and 2018. Patients were included if they had a matching urine culture and blood culture performed within 24 h of admission. We compared patient demographics and underlying co-morbidities between patients admitted with urosepsis secondary to MDR organisms and non-MDR organisms.
Our study included 85 patients admitted with urosepsis. The most common causative pathogen was Escherichia coli, and 34.1% (n = 29) of pathogens were classified as an MDR organism. Patients admitted with urosepsis from long-term care facilities were 2.3 times more likely to have urosepsis due to a MDR organism compared with patients admitted from the community. Patients admitted with urosepsis secondary to a MDR organism were also more likely to have co-morbidities such as diabetes and dementia.
The high rate of antimicrobial resistance in patients admitted with urosepsis poses a challenge in prescribing the most appropriate antibiotics. It is crucial that prescribers follow local antibiotic guidelines for the treatment of urosepsis and are cognisant of the risk of specific patient groups presenting with urosepsis due to MDR organisms.
KeywordsAntibiotic resistance Multi-drug resistant Pathogens Sepsis Urosepsis
We would like to acknowledge Anne Maclellan and Grainne Bowens, Surveillance Scientists, Connolly Hospital for their assistance in data collection.
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 4.Department of Health (2017) Ireland’s national action plan on antimicrobial resistance 2017-2020. iNAP, DublinGoogle Scholar
- 5.Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME (2013) Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Inf Secur 66(5):401–414Google Scholar
- 7.Associated TRC of PCAG on H. Guidelines for the prevention and control of multi-drug resistant organisms (MDRO) excluding MRSA in the healthcare setting. [Internet]. Dublin; 2014. Available from: http://hdl.handle.net/10147/303397. Accessed August 2019
- 9.EARS-Net Report 2011, on Health Services Executive (HSE) - Health protection surveillance centre (HPSC) [Internet]. 2011. Available from: https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2011. Accessed August 2019
- 14.Wagenlehner FME, Pilatz A, Weidner W, Naber KG (2015) Urosepsis: Overview of the diagnostic and treatment challenges. Microbiol Spectr 3(5)Google Scholar